Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pirfenidone

pirfenidone

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of pirfenidone

24 trials tracked of pirfenidone: 8 in phase 3 or 4 and 3 with published results. The most-cited published study has 301 citations.

24Trials tracked
8Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 5 Phase 2 11 Phase 1 1 Other / NA 4
  1. Phase 4 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF Completed · 301 cited
  2. Phase 3 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed · 151 cited
  3. Phase 4 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed · 135 cited
  4. Phase 4 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination Completed
  5. Phase 3 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Completed
  6. Phase 3 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed
Show 18 more trials
  1. Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed
  2. Phase 3 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed
  3. Phase 2 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Completed
  4. Phase 2 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension Completed
  5. Phase 2 Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Completed
  6. Phase 2 Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) Completed
  7. Phase 2 A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease Completed
  8. Phase 2 Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1) Completed
  9. Phase 2 Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Completed
  10. Phase 2 Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis Completed
  11. Phase 2 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction Completed
  12. Phase 2 A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed
  13. Phase 2 A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed
  14. Phase 1 A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood Completed
  15. N/A Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan Completed
  16. N/A A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking Completed
  17. N/A Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis Completed
  18. N/A Dose Reduction and Discontinuation With Anti-Fibrotic Medications Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pirfenidone reduces lung cancer incidence by 73% in IPF patients with a pooled risk ratio of 0.39
Pulmonology & Critical Care Meta-analysis
Pirfenidone reduces lung cancer incidence by 73% in IPF patients with a pooled risk ratio of 0.39 Antifibrotic drugs may lower lung cancer risk in patients with idiopathic pulmonary fibrosis
This systematic review and meta-analysis evaluated antifibrotic therapies in 15582 patients with idiopathic pulmonary fibrosis. The pooled a…
A large review suggests antifibrotic drugs like pirfenidone might lower lung cancer risk in people with idiopathic pulmonary fibrosis, but m…
Jun 2, 2026